GABAvsMagnesium L-Threonate

GABA binds to GABA-A receptors (ligand-gated Cl- channels with alpha1-6, beta1-3, gamma1-3 subunits) and GABA-B receptors (G-protein coupled, Gi/o mediated), reducing neuronal excitability through hyperpolarization. However, supplemental GABA has limited blood-brain barrier penetration due to absence of a dedicated transporter and rapid metabolism by GABA-transaminase and succinate semialdehyde dehydrogenase in periphery. The calming effects may be mediated through: (1) GABA-A and GABA-B receptors in the enteric nervous system (gut-brain axis) — vagal afferents project to the nucleus tractus solitarius and influence limbic regions; (2) small amounts crossing the BBB via paracellular leakage or in individuals with compromised barrier integrity; (3) peripheral effects reducing systemic stress markers (cortisol, heart rate variability). PharmaGABA (Lactobacillus fermentation product) may have better absorption via peptide-like transport or different pharmacokinetics.

The L-threonate carrier forms stable complexes with magnesium and transports it across the blood-brain barrier via specific transporters more effectively than inorganic magnesium salts or other chelated forms. Once in the brain, magnesium acts as a voltage-dependent blocker of the NMDA receptor channel at the physiological magnesium binding site within the ion pore, preventing excessive calcium influx and glutamate-mediated excitotoxicity. Magnesium also serves as a cofactor for over 300 enzymes including those involved in neurotransmitter synthesis (tyrosine hydroxylase, glutamic acid decarboxylase), ATP production (creatine kinase, pyruvate kinase), and DNA/RNA polymerase. Elevated brain magnesium enhances synaptic density and plasticity in the hippocampus and prefrontal cortex, likely through CREB-mediated gene expression and increased density of postsynaptic AMPA receptors.